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Malignant mesothelioma is a tumour that originates from the
mesothelial cells of serous cavities, and is mostly associated with
occupational exposure to asbestos fibres (Mossman et al, 1996). A
typical feature of mesothelioma is its resistance to chemothera-
peutic agents and radiation. A number of different tumours, which
metastasize in pleura may mimic mesothelioma. The most common
problem in this respect is adenocarcinoma. The differential diag-
nosis between mesothelioma and adenocarcinoma is still difficult.
The diagnosis of mesothelioma is usually based on a typical
histopathology combined with several immunohistochemical
markers, which are positive in adenocarcinoma but not in
mesothelioma. The most common markers are B72.3, CD15
(LeuM1), carcinoembryonal antigen (CEA), BER-Ep4, MOC-31
and epithelial membrane antigen (EMA) (Gaffey et al, 1992;
Arber and Weiss, 1993; Demjek and Hjerpe, 1994; Ruitenbeek et
al, 1994; Leers et al, 1998). As far as we know, calretinin may be
the only histochemical marker that is positive in human mesothe-
lioma and negative in adenocarcinoma (Leers et al, 1998). Another
marker which may possibly be used in the differential diagnosis of
mesothelioma is manganese superoxide dismutase (MnSOD); we
have recently observed that the mRNA and specific activities of
MnSOD are highly elevated in mesothelioma cell line cells
compared to non-malignant mesothelial cells (Kinnula et al,
1996). Furthermore, a more recent study carried out in our labora-
tory showed that the MnSOD protein is highly expressed in
tumour biopsies of malignant mesothelioma (Kahlos et al, 1998).
MnSOD is a superoxide radical scavenging mitochondrial
enzyme, which is crucial in protecting cells and tissues against
high oxygen tension and oxidants (Tsan et al, 1990; Wispe et al,
1992). Various cell types of the lung parenchyma have unique
antioxidant enzyme profiles (Kinnula et al, 1995). MnSOD reac-
tivity has been detected in type II pneumocytes and alveolar
macrophages in healthy human lung (Coursin et al, 1996; Lakari 
et al, 1998). It is low or undetectable in healthy human pleural
mesothelium (Kahlos et al, 1998) and weakly stained in human
bronchial epithelium (Kinnula et al, 1994; Coursin et al, 1996;
Lakari et al, 1998). MnSOD is induced by cytokines (Wong and
Goeddel, 1988; Tsan et al, 1992) and asbestos fibres (Mossman et
al, 1986; Janssen et al, 1994) in vitro and by hyperoxia in vivo,
especially in rat pleural mesothelium (Clyde et al, 1993). Very
little is known about the expression of MnSOD in human lung
tumours. Coursin and co-workers showed that the immunoreac-
tivity of MnSOD is variable in human lung adenocarcinoma
(Coursin et al, 1996). With the exception of our recent study
(Kahlos et al, 1998), there are no previous reports on MnSOD
immunoreactivity in pleural tumours.
The aim of this study was to compare the level of MnSOD as
determined by immunohistochemistry with semiquantitation in
malignant pleural mesothelioma and metastatic adenocarcinoma
of the pleura, and to test the hypothesis that MnSOD could be
used as an additional marker in the diagnosis of human mesothe-
lioma.
MATERIALS AND METHODS
Patients, handling of specimens, and diagnostic
aspects
Histopathologically typical cases of malignant mesothelioma and
metastatic adenocarcinoma of the pleura were retrieved from the
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files of the Department of Pathology, Oulu University Hospital, by
re-evaluating thoracoscopic pleural biopsies obtained during
1976–1997. Fifty-six patients (11 women and 45 men), of whom 35
had a malignant mesothelioma and 21 a metastatic adenocarcinoma
of the pleura, were included in the study. Of the 24 mesothelioma
patients with adequate data available, 16 (67%) had evidence of
occupational exposure to asbestos as established from the patient
history. The biopsy material was fixed in 10% formalin and the
specimens were then dehydrated and embedded in paraffin.
The malignant mesotheliomas were classified into epithelial,
sarcomatoid (fibrous, i.e. spindle-cell) or biphasic subtypes
(WHO, 1981). The malignant mesotheliomas were distinguished
from the metastatic adenocarcinomas of the pleura on the basis 
of the presence of intracellular or extracellular hyaluronic acid 
in mesothelioma, while the adenocarcinomas usually contained
intracellular, mostly globular, PAS-positive and diastase-resistant
epithelial mucin. In problematic cases diagnostic electron
microscopy was performed to demonstrate typical long microvilli
in malignant mesotheliomas, but not in metastatic adenocarci-
nomas (Hammar, 1994). Immunohistochemical staining against
certain antigens, such as cytokeratins, EMA and CEA, has been
increasingly used in the differential diagnosis between malignant
mesothelioma and metastatic adenocarcinoma of the pleura.
Accordingly, metastatic adenocarcinomas of the pleura were diag-
nosed on the basis of CEA-positivity and often contained intra-
cytoplasmic EMA-positivity, while malignant mesotheliomas
were CEA-negative and occasionally exhibited membrane-bound
positivity for EMA (van der Kwast et al, 1988; Hammar, 1994).
Cell cultures
Mesothelioma cell lines (M14K, M24K, M25K, M28K, M33K,
M38K) have been established from the tumour tissue of six
untreated mesothelioma patients and one (M10K) from a metas-
tasis of mesothelioma in a patient who had received both radiation
and chemotherapy before sample (Pelin-Enlund et al, 1990; Pelin
et al, 1994; Ungar et al, 1994). Human lung adenocarcinoma A549
cells and non-malignant SV40 transformed Met5A (Ke et al, 1989)
mesothelial cells were obtained from American Type Culture
Collection (Rockville, MD, USA). The mesothelioma and Met5A
cells were grown in RPMI-1640 medium supplemented with 10%
fetal calf serum, 100 U ml–1 penicillin, 100 mg ml–1 streptomycin
and 0.03% L-glutamine (all from LTI Life Technologies, Paisley,
UK) at 37°C in a 5% carbon dioxide atmosphere. The A549 cells
were grown in similar atmospheric conditions in minimum
essential medium supplemented with L-glutamine and penicillin–
streptomycin as above (all from LTI Life Technologies).
Immunohistochemistry
One representative paraffin block was selected for immuno-
histochemical stainings. Four-micron-thick sections were cut and
processed further within a few days. They were deparaffinized 
in xylene, and re-hydrated in a descending ethanol series.
Endogenous peroxidase was consumed by incubating the sections
in 0.1% hydrogen peroxide in methanol for 10 min. In order to
enhance the immunoreactivity for MnSOD, the microwave-
pretreatment antigen retrieval technique was also applied to each
specimen. Before incubation with the primary antibody the slides
were placed in a 0.1 M citrate buffer (pH 6.0) and boiled for 2 min
at 850 W, and after that for 3 min at 350 W. A polyclonal antibody
for MnSOD was a gift from Prof. James D Crapo (National Jewish
Medical Center, Denver, CO, USA). This antihuman recombinant
MnSOD (rh MnSOD) antibody has been prepared by immunizing
rabbits with rh MnSOD (Boehringer Mannheim, Indianapolis, IL,
USA). The antiserum in immunoblots produces only one band at a
molecular weight of MnSOD, and preincubation of the antiserum
with rh MnSOD abolishes the reaction (Kinnula et al, 1994). The
sections were incubated with the primary antibody (anti-MnSOD
with a dilution 1:1000) at room temperature for 2 h, followed 
by a biotinylated swine anti-rabbit secondary antibody (at a
dilution of 1:200 for 30 min) and the avidin–biotin–peroxidase
complex (both from Dakopatts, Glostrup, Denmark). The colour
was developed with diaminobenzidine. The sections were counter-
stained with a light haematoxylin stain. The negative controls were
established substituting phosphate-buffered saline (PBS) at pH 7.2
and normal rabbit serum for the primary antibody.
Western blotting
The cells were mixed with the electrophoresis sample buffer and
boiled for 5 min at 95°C; 50 mg of cell protein was applied per lane
to a 12% sodium dodecyl sulphate polyacrylamide gel (Laemmli,
1970). The gel was electrophoresed for 1.5 h (90 V) at room
temperature, the protein was transferred (45 min, 100 V) onto
Hybond ECL nitrocellulose membranes (Amersham, Arlington
Heights, IL, USA) in a Mini-PROTEAN II Cell (Bio-Rad,
Hercules, CA, USA). The blotted membrane was incubated with
rabbit antibody to recombinant human MnSOD (1:10 000) (Dr JD
Crapo) followed by donkey anti-rabbit secondary antibody 
(1:30 000) conjugated to horseradish peroxidase (Amersham).
MnSOD was detected by an enhanced chemiluminescence system
(ECL; Amersham), and the luminol excitation was imaged on X-
ray film. b-actin expression of the cells was detected by reprobing
the same membranes with a monoclonal anti-actin antibody
(1:2500) (Sigma, St Louis, MO, USA) followed by sheep anti-
mouse antibody conjugated to horseradish peroxidase (1:3000)
(Amersham). Cell protein was measured using the Bio-Rad
method (Bradford, 1976).
Light microscopical evaluation
For immunohistochemical staining the whole tissue section was
evaluated by light microscopy and the results were assessed semi-
quantitatively by grading the staining intensity of the tumour cells
as follows: negative (–), weak (+), moderate (++), and strong
(+++) immunoreactivity. When microwave antigen retrieval was
used, the percentage of the whole cell population showing any
immunoreactivity was also evaluated. All the sections were evalu-
ated blindly by two of the authors.
Statistical analysis
SPSS 7.0 for Windows (Chicago, IL, USA) was used for the statis-
tical analyses. The significance between the groups was compared
using Fisher’s exact test. The survival of the patients in relation to
MnSOD reactivity was assessed by the log-rank and Breslow tests.
P-values of less than 0.05 were considered statistically significant.1024 K Kahlos et al
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RESULTS
The MnSOD immunoreactivity values and clinical characteristics
of the patients with pleural malignant mesothelioma or metastatic
adenocarcinoma are shown in Tables 1 and 2. Fifteen of the 35
malignant mesotheliomas without microwave pretreatment and 
23 after microwave antigen retrieval showed moderate or strong
MnSOD immunoreactivity (Table 1). The figures for metastatic
adenocarcinoma of the pleura were one and two out of 21 respec-
tively (Table 2). Thus, malignant mesotheliomas showed signifi-
cantly more often moderate or strong MnSOD immunoreactivity
than metastatic adenocarcinomas of the pleura either without 
(P = 0.002 by Fisher’s exact probability test; Table 3) or after
microwave antigen retrieval (P < 0.001 by Fisher’s exact proba-
bility test; Table 4). The histological type of the mesothelioma also
appeared to affect MnSOD immunoreactivity; strong MnSOD
immunoreactivity was observed only in epithelial and biphasic but
not in sarcomatoid mesotheliomas (P = 0.03 by Fisher’s exact test
without microwave pretreatment, P = 0.02 by Fisher’s exact test
after microwave antigen retrieval; Table 1). Some MnSOD reac-
tivity could also be detected in the stromal cells of mesothelioma
(not shown) and adenocarcinomas (Figure 1 C,D). Even though
microwave antigen retrieval clearly improved MnSOD immuno-
reactivity, it did not change the characteristic staining pattern of
the tumours (Figure 1). The improvement of MnSOD immuno-
reactivity obtained by microwave antigen retrieval in both tumour
types and especially in malignant mesotheliomas is shown in
Tables 5 and 6. The reactive mesothelium, which was seen in a few
cases along with tumour tissue, also showed prominent immuno-
reactivity for MnSOD. In these cases immunoreactivity in the
surrounding reactive mesothelium was clearly stronger than in the
metastatic adenocarcinomas (Figure 2). MnSOD reactivity did not
differ between the mesothelioma patients with or without previous
exposure to asbestos fibres. No staining was seen in the negative
controls, where the primary antibody had been replaced by rabbit
serum or PBS.
The immunoreactivity of MnSOD in mesothelioma was also
assessed in relation to the survival of the patients. The short-term,
but not the long-term, survival of the mesothelioma patients with
moderate or strong MnSOD immunoreactivity after microwave
retrieval was slightly better than those with negative or weak
MnSOD immunoreactivity (median survival 8 and 2 months
respectively,  P = 0.057 by log-rank test, P = 0.008 by Breslow test,
Figure 3). No significant difference in survival was seen between
the patients with epithelial, biphasic or sarcomatoid subtypes of
mesothelioma (P = 0.18 by log-rank test).
Table 1 Clinical information on patients with malignant mesothelioma and MnSOD immunoreactivity of the tumours without
and after microwave antigen retrieval
Patient no. Histological type Sex Age MnSOD immunoreactivity MnSOD immunoreactivity
without microwave after microwave retrieval
retrieval
Epithelial M 75 – +++
Epithelial F 70 – ++
Epithelial M 63 – ++
Epithelial M 73 – +
Epithelial M 64 – +
Epithelial M 54 – +
Epithelial M 78 – +
Epithelial M 70 – +
Epithelial M 63 + ++
Epithelial M 59 + +
Epithelial M 57 + ++
Epithelial M 51 ++ ++
Epithelial M 46 ++ +++
Epithelial M 67 ++ ++
Epithelial M 78 ++ ++
Epithelial M 68 ++ +++
Epithelial M 56 +++ +++
Epithelial M 66 +++ +++
Epithelial M 50 +++ +++
Epithelial M 73 +++ +++
Epithelial M 59 +++ +++
Epithelial M 79 +++ +++
Biphasic M 57 – ++
Biphasic F 57 ++ +++
Biphasic M 70 ++ +++
Biphasic M 68 ++ +
Sarcomatoid F 42 – +
Sarcomatoid M 59 – +
Sarcomatoid M 63 – ++
Sarcomatoid M 52 – +
Sarcomatoid F 33 – ++
Sarcomatoid M 71 – ++
Sarcomatoid M 67 – ++
Sarcomatoid F 55 + +
Sarcomatoid M 73 ++ +
1
2
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The expression of MnSOD was also investigated in non-malig-
nant and malignant cell lines, including non-malignant human
pleural mesothelial (Met5A) cells, lung adenocarcinoma A549
cells and seven pleural mesothelioma cell lines. Western blotting
revealed low MnSOD expression in mesothelial cells and adeno-
carcinoma cells, while the immunoreactivity of MnSOD was
prominent, albeit variable, in all malignant mesothelioma cell line
cells (Figure 4). The antibody showed excellent detection of the
MnSOD protein with no background staining or impurities.
DISCUSSION
These results indicate that MnSOD immunoreactivity may be used
as an additional diagnostic marker in the differential diagnosis
between malignant mesothelioma and metastatic adenocarcinoma
of the pleura. All mesotheliomas showed at least some MnSOD
immunoreactivity (when a microwave pretreatment technique was
used), while metastatic adenocarcinomas of the pleura tended to be
either negative or only slightly positive. MnSOD immuno-
reactivity was strong only in mesotheliomas but not in any of the
metastatic adenocarcinomas investigated.
Numerous studies have indicated that MnSOD is usually low in
malignant tumours, whereas the expression of other antioxidant
enzymes is variable (Oberley and Buettner, 1979; Oberley and
Oberley, 1997). In addition to pleural mesothelioma (Kahlos et al,
1998) certain tumours of the central nervous system, thyroid
gland, kidney and gastrointestinal tract also contain high levels of
MnSOD compared to their non-malignant counterparts (Nishida et
al, 1993; Cobbs et al, 1996; Oberley and Oberley, 1997; Janssen et
al, 1998). In some malignancies MnSOD expression appears to be
associated with the degree of differentiation of the tumour
(Landriscina et al, 1996). To our knowledge there is only one study
in which MnSOD immunoreactivity has been examined in human
lung adenocarcinoma. In that particular study the three biopsies of
adenocarcinoma showed variable MnSOD immunoreactivities,
and in agreement with our results both the tumour and stromal
cells were positive for MnSOD (Coursin et al, 1996). So far, no
biopsies of mesothelioma have been included in that or any other
study, with the exception of our recent study on human mesothe-
lioma (Kahlos et al, 1998). A previous study on rat lung showed
that the mRNA of MnSOD is highly up-regulated, especially in the
mesothelium of hyperoxia-exposed rats (Clyde et al, 1993). In
agreement with this, we found that MnSOD immunoreactivity was
enhanced in non-malignant reactive mesothelium, but not in 
non-malignant airway epithelium. The prominent induction of
MnSOD, especially in reactive mesothelial cells, is unclear but
Table 2 Clinical information on patients with metastatic adenocarcinoma of the pleura and MnSOD immunoreactivity
in tumours without and after microwave antigen retrieval
Patient no. Primary Sex Age MnSOD immunoreactivity MnSOD immunoreactivity
tumour without microwave after microwave retrieval
Bile duct M 65 + +
Breast F 43 – +
Breast F 65 – +
Breast F 70 + +
Kidney F 66 – +
Kidney M 53 + –
Lung M 68 – –
Lung F 60 – –
Lung M 55 – +
Lung M 63 – –
Lung M 49 – +
Lung M 69 – +
Lung M 68 – –
Lung M 76 – +
Lung M 71 – –
Lung M 64 – +
Lung M 60 + +
Lung M 49 + +
Lung M 79 + –
Lung F 65 ++ ++
Unknown M 75 + ++
Table 3 MnSOD immunoreactivity of malignant mesotheliomas and metastatic adenocarcinomas
of the pleura without microwave pretreatment
Tumour type MnSOD immunoreactivity
Negative or Weak Moderate or Strong
(– or +) (++ or +++)
No. of cases No. of cases
Mesothelioma 20 15
Metastatic adenocarcinoma of the pleura 20 1
P = 0.002 by Fisher’s exact test.
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Figure 1 MnSOD immunoreactivity in epithelial malignant mesothelioma (A, B) and metastatic adenocarcinoma of the pleura (C, D) without (A, C) and after
microwave antigen retrieval (B, D). The MnSOD immunostaining is clearly stronger after microwave pretreatment. Magnification ´ 400
Table 4 MnSOD immunoreactivity of mesotheliomas and metastatic adenocarcinomas of the pleura after
microwave antigen retrieval
Tumour type MnSOD immunoreactivity
Negative or Weak Moderate or Strong
(– or +) (++ or +++)
No. of cases No. of cases
Mesothelioma 12 23
Metastatic adenocarcinoma of pleura 19 2
P < 0.001 by Fisher’s exact test.
Table 5 MnSOD immunoreactivity of mesotheliomas without and after microwave antigen retrieval
MnSOD immunoreactivity
Negative Weak Moderate or strong
(–) (+) (++ or +++)
(No. of cases) (No. of cases) (No. of cases)
Without microwave pretreatment 16 4 15
After microwave antigen retrieval 0 12 23
Negative vs weak-strong: P < 0.00001 by Fisher’s exact test, negative-weak vs moderate-strong: P = 0.046
by Fisher’s exact test.MnSOD as a diagnostic marker for mesothelioma 1027
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consistent with previous studies showing that MnSOD is highly
up-regulated by cytokines such as tumour necrosis factor-a (TNF-
a) (Wong and Goeddel, 1988; Kinnula et al, 1995) also in Met5A
cells (Pietarinen-Runtti et al, 1996). Since MnSOD may be
induced both in reactive and malignant mesothelium, it cannot be
used in the differential diagnosis between non-malignant reactive
mesothelium and malignant mesothelioma.
Not only the type of the tumour, but also the immunohistochem-
ical technique itself may have effects on the intensity of MnSOD
immunoreactivity. Non-specific immunoreactivity had been ex-
cluded by reactions with rabbit serum and PBS. Since histochemical
methods are semiquantitative and may vary in different laboratories,
all samples were examined blindly by two observers both with and
without microwave pretreatment for antigen retrieval. Van Driel and
co-workers reported low MnSOD expression in colorectal neo-
plasms, and in that study no microwave pretreatment was used (Van
Driel et al, 1997). In the study of Cobbs and co-workers malignant
nervous system tumours showed prominent MnSOD immuno-
reactivity without microwave pretreatment (Cobbs et al, 1996). In
the study of Coursin and co-workers no such pretreatment was used,
and the immunoreactivities for MnSOD in their three adenocarci-
noma biopsies were variable (Coursin et al, 1996). In our recent
study no such treatment was used either and MnSOD was highly
stained in all the six mesothelioma biopsies and negative in normal
mesothelium (Kahlos et al, 1998). In the present study a remarkable
portion of mesothelioma biopsies were negative without microwave
antigen retrieval. The staining was intensified with the microwave
pretreatment, so that none of the mesothelioma biopsies remained
negative, whereas one-third of the 21 metastatic adenocarcinoma
biopsies still remained negative. Furthermore, one-third of the
mesothelioma biopsies showed strong MnSOD immunoreactivity,
Table 6 MnSOD immunoreactivity of metastatic adenocarcinoma of the pleura without and after
microwave antigen retrieval
MnSOD immunoreactivity
Negative Weak Moderate or strong
(–) (+) (++ or +++)
(No. of cases) (No. of cases) (No. of cases)
Without microwave pretreatment 13 7 1
After microwave antigen retrieval 6 13 2
Negative vs weak-strong: P = 0.03 by Fisher’s exact test, negative-weak vs moderate-strong: P = 0.5 by
Fisher’s exact test.
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Figure 2 MnSOD immunoreactivity in reactive mesothelium in comparison
with metastatic adenocarcinoma of the pleura. Reactive mesothelium below
shows stronger immunoreactivity for MnSOD than the metastatic
adenocarcinoma above. Magnification ´400
Figure 3 Survival in relation to MnSOD immunoreactivity in malignant
mesothelioma. The patients with malignant mesothelioma showing moderate
or strong MnSOD immunoreactivity after microwave antigen retrieval had a
tendency for better short term prognosis than those with negative or weak
MnSOD immunoreactivity (P = 0.057 by log-rank test, P = 0.006 by Breslow
test)
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Figure 4 A representative Western blot analysis showing moderate or high
MnSOD immunoreactive protein (21 kDa) in seven mesothelioma cell lines
(M10K, M14K, M24K, M25K, M28K, M33K, M38K), and low MnSOD
immunoreactivity in non-malignant mesothelial Met5A cells and in lung
adenocarcinoma A549 cells. b-actin expression was detected to confirm the
loading homogeneity (arrow)1028 K Kahlos et al
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while MnSOD immunoreactivity was never strong in adenocarci-
nomas. Thus strong MnSOD immunoreactivity supports the diag-
nosis of mesothelioma. If the MnSOD immunoreactivity is weak or
negative, the differential diagnosis between mesothelioma and
adenocarcinoma remains unclear.
Mesothelioma is mostly associated with exposure to asbestos
fibres, and asbestos fibres are known to induce MnSOD in a
variety of cells (Mossman et al, 1986; Clyde et al, 1993). The
history of previous asbestos exposure was not associated with the
intensity of MnSOD immunostaining. However, retrospective
information on the exposure of mesothelioma patients to asbestos
may underestimate the number of exposed patients. In our
previous study, MnSOD reactivity in mesothelioma cells was not
associated with the fibre content of the lung (Kahlos et al, 1998).
Furthermore, mesothelioma can also develop on patients who have
not been exposed to asbestos fibres and even in lungs with low or
undetectable levels of asbestos fibres.
Given that antioxidant enzymes, such as superoxide dismutase,
protect cells against oxidant stress, they may also have prognostic
significance in malignant diseases. Recently, Van Driel and co-
workers did not find differences in the survival of their patients
with colorectal carcinoma in relation to CuZnSOD immunoreac-
tivity (Van Driel et al, 1997). On the other hand, Janssen and co-
workers suggested that high MnSOD reactivity in gastrointestinal
cancer may be associated with poor survival (Janssen et al, 1998).
The present study suggested that high MnSOD immunoreactivity
might be associated with a better short-term prognosis. However,
the differences in survival were very small. Furthermore, the prog-
nosis of mesothelioma patients is very poor as was also observed
in this study.
Even though the reactivities of various antioxidant enzymes are
known to be decreased in cultured cells (Kinnula et al, 1992,
1994), this is not the case in mesothelioma cell line cells. We have
previously found that several mesothelioma cell line cells have
higher mRNA level and specific activity of MnSOD than non-
malignant Met5A mesothelial cells or whole-lung homogenate
(Kinnula et al, 1996). In agreement with these findings, this study
showed that all the seven mesothelioma cell lines had higher
MnSOD reactivities than Met5A cells. This result is also consis-
tent with our recent finding showing very low reactivity in Met5A
cells, weak reactivity in M14K cells and strong reactivity in M38K
cells immunocytochemically when this same antibody has been
used (Kahlos et al, 1998). A549 cells which have originally been
established from alveolar epithelial type II pnemocytes also
contained lower MnSOD immunoreactivity than any of the inves-
tigated mesothelioma cells.
In conclusion, high MnSOD is characteristic of human malig-
nant mesothelioma, and MnSOD immunohistochemistry can aid
the differential diagnosis of mesothelioma and metastatic adeno-
carcinoma.
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